Phase II study of disitamab vedotin (RC48) in combination with tislelizumab and bevacizumab in patients (Pts) with HER2 alterations locally advanced or metastatic NSCLC: Primary analysis results of RESOLUTION.
Year: 2025
Type: article
Study design: Clinical Trial
Source: Journal of Clinical Oncology
Authors: Jianing Chen, Xinyu Zhang, Li Liu, Jing Zhao, Guanghui Gao, Jun Zhu, Sha Zhao, ChunXia Su
Institutions: Shanghai Pulmonary Hospital, Tongji University
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410805146